Danske Bank A S Invests $6.41 Million in Lantheus Holdings, Inc. $LNTH

Danske Bank A S acquired a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 57,791 shares of the medical equipment provider’s stock, valued at approximately $6,411,000. Danske Bank A S owned about 0.09% of Lantheus at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Deutsche Bank AG acquired a new position in Lantheus during the 2nd quarter valued at about $27,596,000. Perigon Wealth Management LLC acquired a new stake in Lantheus in the second quarter worth about $391,000. Rice Hall James & Associates LLC acquired a new stake in Lantheus in the second quarter worth about $4,852,000. Persistent Asset Partners Ltd purchased a new stake in shares of Lantheus during the second quarter worth about $433,000. Finally, Chase Investment Counsel Corp acquired a new position in shares of Lantheus during the second quarter valued at about $2,218,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Wall Street Zen lowered shares of Lantheus from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Citigroup reissued an “outperform” rating on shares of Lantheus in a research report on Friday, May 8th. Citizens Jmp restated a “market outperform” rating and set a $115.00 price target on shares of Lantheus in a research note on Monday, June 29th. CJS Securities cut shares of Lantheus from a “market outperform” rating to a “market perform” rating in a report on Tuesday, August 4th. Finally, Weiss Ratings downgraded shares of Lantheus from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, August 13th. Four investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $108.11.

Lantheus Price Performance

Shares of NASDAQ LNTH opened at $99.97 on Friday. The business’s 50 day moving average price is $104.08 and its 200 day moving average price is $90.35. The firm has a market cap of $6.53 billion, a P/E ratio of 24.15 and a beta of -0.03. Lantheus Holdings, Inc. has a 52 week low of $49.67 and a 52 week high of $111.86. The company has a quick ratio of 2.89, a current ratio of 3.06 and a debt-to-equity ratio of 0.43.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.30 by $0.25. The company had revenue of $388.18 million during the quarter, compared to analyst estimates of $363.23 million. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. Lantheus’s revenue for the quarter was up 2.7% compared to the same quarter last year. During the same period last year, the firm posted $1.57 EPS. On average, sell-side analysts expect that Lantheus Holdings, Inc. will post 4.48 earnings per share for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.